Open an account

Haemonetics

HAE · NYSE

$118.21−$0.52 (−0.44%)TodayMarket closed ·
Prev close $118.73

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 3,023 full-time employees. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). The company also offers solutions for structural heart and endovascular procedures.

Employees
3,023
Headquarters
Boston, Massachusetts
Listed
Oct 17, 1979
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
haemonetics.com

HAE key statistics

Market cap
5.40B
Price-earnings ratio
57.36
Dividend yield
—
Average volume
695.28K
Volume
585.06K
Open price
$119.50
High today
$120.50
Low today
$117.21
52 Week high
$123.77
52 Week low
$48.98

Haemonetics (HAE) at a glance

As of Oct 20, 2026, Haemonetics (HAE) shares are priced at $118.21, giving the company a market cap of 5.40B and a price-to-earnings ratio of 57.36.

Today the stock has traded between $117.21 and $120.50. The current price is 0.9% above the day's low and 1.9% below its high.

Volume so far is 585.06K shares, in line with the average of 695.28K shares a day.

Over the past year Haemonetics has ranged from $48.98 to $123.77, and now sits 93% of the way up that range.

Haemonetics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $1.14 per share against an estimate of $1.09.

The average analyst price target is $116.62, 1.3% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

70%of 10 analyst ratings say Buy
  • Buy70.0%
  • Hold30.0%
  • Sell0.0%
Price target · 11 analystsAvg $116.62
Low
$95.95
Now
$118.21
High
$131.25

HAE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 2.2% on average.

  1. Q4 FY24: reported $0.90 per share against an estimate of $0.9002
  2. Q1 FY25: reported $1.02 per share against an estimate of $1.02
  3. Q2 FY25: reported $1.12 per share against an estimate of $1.08
  4. Q3 FY25: reported $1.19 per share against an estimate of $1.18
  5. Q4 FY25: reported $1.24 per share against an estimate of $1.23
  6. Q1 FY26: reported $1.29 per share against an estimate of $1.28
  7. Q1 FY27: reported $1.14 per share against an estimate of $1.09
  8. Q2 FY26: reported $1.14 per share against an estimate of $1.09

HAE news

  • Press releasePRNewswire

    Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line

  • Press releasePRNewswire

    Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

  • Akanksha Bakshi

    Haemonetics Stock Hits 52-Week High - Here's Why

  • Haemonetics Q1 2027 Earnings Call Transcript

  • Press releasePRNewswire

    Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

  • Press releasePRNewswire

    AZENTA ANNOUNCES LEADERSHIP TRANSITION

  • Henry Khederian

    Haemonetics Shares Hit New 52-Week High: What's Happening?

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as Haemonetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.